Pro/Con Debate "Cost-effectiveness of maintenance chemotherapy for NSCLC"
Symposium Chairs: T. Berghmans (Brussels, Belgium), L. Schmidt (Munster, Germany)
Aims: Maintenance chemotherapy has been shown to be associated with improved outcomes for patients with advanced non-small cell lung cancer. However, the definition of maintenance is variable, the data published in the literature are heterogeneous and the cost of the drugs with which there is a potential benefit is high. The purpose of the session will be to discuss the practical advantages and disadvantages of maintenance in order to allow better therapeutic evidence-based decisions.